Drugs / Bictegravir/emtricitabine/tenofovir alafenamide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04132674 | Nov 2018 → Jun 2020 | HIV infectious disease, substance abuse | Vancouver Infectious Diseases Centre | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bictegravir/emtricitabine/tenofovir alafenamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04132674 ↗ |
| Route | Oral | “Taking one oral tablet of B/F/TAF once-daily for 72 weeks” NCT04132674 ↗ |